Pan-Cancer Study of the Prognosistic Value of Selenium Phosphate Synthase 1.

This study sought to determine the mean prognostic usefulness of seleniumphosphate synthase () by investigating its expression in 33 human malignancies and its relationship to tumor immunity. The expression of selenophosphate synthase 1 () in 33 human malignant tumors was examined using the Genotype-Tissue Expression (GTEx), Cancer Genome Atlas (TCGA), and TIMER databases. Furthermore, the TCGA cohort was used to investigate relationships between and immunological checkpoint genes (ICGs), tumor mutation burden (TMB), microsatellite instability (MSI), and DNA mismatch repair genes (MMRs). To establish independent risk factors and calculate survival probabilities for liver hepatocellular carcinoma (LIHC) and brain lower-grade glioma (LGG), Cox regression models and Kaplan-Meier curves were utilized. Eventually, the Genomics of Cancer Drug Sensitivity (GDSC) database was used to evaluate the drug sensitivity in LGG and LIHC patients with high expression. Overall, in numerous tumor tissues, was highly expressed, and it significantly linked with the prognosis of LGG, ACC, and LIHC ( < .05). Furthermore, in numerous cancers, expression was linked to tumor-infiltrating immune cells (TIICs), TMB, MSI, and MMRs. According to univariate and multivariate Cox analyses, expression was significant for patients with LGG and LIHC. High expression has a better prognosis for LGG, while low expression has a better prognosis for LIHC. Chemotherapy was advised for LGG patients, particularly for those with high expression because it can predict how responsive patients will be to 5-Fluorouracil and Temozolomide. This interaction between and chemoradiotherapy has a positive clinical impact and may be used as evidence for chemotherapy for LGG and LIHC patients.